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THE POTENTIAL OF CRL4DCAF1 AND KSR1 AS THERAPEUTIC 
TARGETS IN MERLIN-DEFICIENT MENINGIOMA
Ms Jade Lyons Rimmer, Dr Daniele Baiz, Ms Emanuela Ercolano,  
Prof Oliver Hanemann; Plymouth University
BACKGROUND: Merlin-deficient meningiomas are caused by mutations 
in the Neurofibromin 2 gene and occur in approximately 60% of sporadic 
meningiomas. Merlin loss is commonly associated with the genetic condition 
Neurofibromatosis type 2, leading to the development of multiple low grade 
tumours including schwannoma and meningioma. Currently, the only treat-
ment for low grade meningioma is (radio)surgery therefore identification of 
novel drug targets is vital. Previous studies have shown that Kinase suppressor 
of Ras 1 (KSR1) is a potential therapeutic target in schwannoma and that the 
E3 ubiquitin ligase, CRL4DCAF1, binds to KSR1. The aim of this project is to 
investigate the interaction between CRL4DCAF1 and KSR1 to determine if 
targeting this protein complex in meningioma holds therapeutic value. METH-
ODS: HEK293T cells were transfected with KSR1 constructs and interactions 
with CRL4DCAF1 were investigated by immunoprecipitation. Immunohisto-
chemistry, cell fractionation and Western blot were used to analyse DCAF1 and 
KSR1 expression and localization in primary human meningioma. A shRNA 
construct was used to knock down DCAF1 and APS_2_79 was used to inhibit 
KSR1. RESULTS: KSR1 interacts via the N-term with DCAF1 and is ubiq-
uitinated at the C-term in the NF+/+ model which may be DCAF1 depend-
ent. Immunohistochemistry showed increased DCAF1 and KSR1 expression 
in Merlin-deficient meningiomas compared with normal meninges, whereas 
Western blot analysis showed variable protein expression. DCAF1 knockdown 
led to a reduction of nuclear pERK1/2 and a significant decrease in prolifera-
tion of meningioma cells but pERK1/2 and Cyclin D1 levels were unchanged. 
Combination of shDCAF1 and APS_2_79, a specific KSR1 inhibitor, reduced 
pERK and proliferation in both BenMen-1, a benign meningioma cell line and 
primary meningioma. Therefore, targeting both DCAF1 and KSR1 represents 
an attractive novel therapeutic strategy in meningioma.
5-ALA FLUORESCENCE BASED ISOLATION OF MINORITY 
POPULATION GBM CELLS IDENTIFIES PUTATIVE INVASION 
ASSOCIATED MOLECULAR CHANGES
Dr Maria de los Angeles Estevez-Cebrero, Dr Anbarasu Lourdusamy,  
Dr Ruman Rahman, Dr Stuart Smith; The University of Nottingham
INTRODUCTION: Glioblastoma (GBM) is a highly pleomorphic poly-
clonal tumour with molecular abnormalities varying temporo-spatially 
(intra-tumour heterogeneity), one mechanism of therapy resistance. Fluo-
rescence guided resection (FGR) is performed with prior administration of 
5-aminolevulinic acid (5-ALA) leading to individually fluorescent tumour 
cells mixed within a background population of non-neoplastic neural cells in 
the invasive region beyond the “pure” tumour. We have isolated this invasive 
tumour population by fluorescence activated cell sorting (FACS) to allow the 
study of invasive tumour cells without an overwhelming background “nor-
mal” signal. We conducted genome wide gene expression of phenotypically 
distinct areas of the tumour and from fluorescent/non-fluorescent cancer/
non-cancer cells purified from the invasive zone respectively.METHODS: 
We performed genome-wide gene expression analysis on 14 glioma samples 
from three different GBM patients including samples from tumour core, rim, 
invasive margin and GBM cells from the invasive margin that were isolated 
by 5-ALA assisted FACS. RESULTS: Statistical analysis by linear models for 
microarray data identified 325 differentially expressed genes between FACS 
positive cells and other tumour regions (adjusted P-value < 0.05), of these, 
50 genes were upregulated in all comparisons. These transcriptomic changes 
orchestrate MAPK (DUSP1, DUSP2, DUSP10 and FOSB), chemokine signal-
ling pathways (CXCL2, CXCL3, CCL20 and NFKB1) and negative regula-
tion of cell proliferation (EREG and KLF6). In contrast, 29 downregulated 
genes in FACS positive cells were enriched with signal transduction (DDR2 
and MTSS1L) and ECM-receptor interaction (COL4A1, COL4A2, and 
HSPG2). DISCUSSION: Residual cells responsible for GBM recurrence in 
the invasive zone are shown to be not only phenotypically different but 
also exhibiting activation of distinct molecular pathways and biological 
processes. These unique molecular features offer hope for developing more 
efficacious targeted therapies focusing on this population rather than the 
bulk tumour that has been the subject of most historical analyses.
AN EPIGENETICALLY CONTROLLED PML/SLIT AXIS AT 
THE ROOT OF CELL MIGRATION IN BOTH NORMAL AND 
NEOPLASTIC CELLS IN THE CNS
Dr A Deli, Dr Valeria Amodeo, Dr Joanne Betts, Dr Stefano Bartesaghi,  
Dr Mikaella Vouri, Dr Rozita Roshani, Dr Sara Galavotti,  
Ms Ying Zhang, Dr Matthew Ellis, Ms Joanne Lau,  
Ms Sarah Oberndorfer, Dr AnaLeite, Dr David Dinsdale,  
Prof Chris Jones, Prof Pierluigi Nicotera, Dr David Michod,  
Prof Sebastian Brandner, Prof Paolo Salomoni; UCL Cancer Institute The 
Paul O’Gorman Building
In the central nervous system (CNS), regulation of nuclear function 
has been implicated in the control of cell cycle and migratory processes 
during neurogenesis. Alterations of these processes can lead to neoplastic 
transformation of neural stem cells (NSCs) and glioblastoma multiforme 
(GBM). The ability of GBM cells to migrate through the brain parenchyma 
represents a key factor underlying GBM aggressiveness and resistance to 
treatment. Notably, brain cancer cells use the same routes utilized by neu-
roblasts/immature neurons and NSCs, suggesting a neurobiological root of 
brain cancer migration. However, our understanding of potentially com-
mon mechanisms regulating cell migration/invasion during neurogenesis 
and brain tumourigenesis remains limited. Our previous work has impli-
cated the Promyelocytic Leukaemia protein (PML), the essential component 
of the PML nuclear body (PML-NB), in regulation of embryonic neurogen-
esis via its ability to control proliferation in NSCs. We set out to investigate 
the role of PML in adult neurogenesis and GBM. Loss of PML leads to 
impaired NSC and neuroblast migration and to a smaller olfactory bulb 
in the adult mouse brain. A similar migration defect is observed in primary 
GBM cells where PML expression has been knocked down. Mechanisti-
cally, PML controls cell migration in both mouse NSCs and primary GBM 
cells via down-regulation of Slit genes, which are key regulators of axon 
guidance during development. Changes in Slits transcription upon PML 
kd are caused by global reduction of the repressive H3K27me3 epigenetic 
mark. This is associated with its redistribution to nuclear lamina-associated 
domains (LADs). Finally, PML controls tumor invasion and survival in an 
orthotopic animal model and inversely correlates with patient prognosis 
in GBM. Taken together, these findings support a model whereby PML-
mediated modifications of chromatin structure and function regulate cell 
migration during normal neurogenesis and brain tumorigenesis, suggesting 
a neurobiological root of brain cancer invasion.
EPIGENETIC INACTIVATION OF ARGININE BIOSYNTHESIS GENES 
IN PAEDIATRIC INTRACRANIAL EPENDYMOMA
Dr Katherine Karakoula, Dr Nelofer Syed, Dr Thomas Jacques,  
Mrs Kim Phipps, Mr Dominic Thompson, Prof John Darling,  
Prof Tracy Warr; University of Wolverhampton
Aberrant cellular metabolism is recognized as a major event in the growth 
and development of many cancers and the targetting of metabolic defects in 
tumour cells represents a new therapeutic opportunity. For example, cells 
that do not express sufficient levels of argininosuccinate synthetase-1 (ASS1) 
or argininosuccinate lyase (ASL) become auxotrophic for arginine and 
require exogenous supply. Arginine deprivation using arginine deiminase 
(ADI-PEG20) is currently under evaluation in clinical trials for adult GBM. 
In this study, we investigated the arginine biosynthesis pathway in paediatric 
intracranial ependymoma, comprising 24 fresh frozen biopsies and 17 short-
term cell cultures of low passage (<10). The methylation status of ASS1 and 
ASL was assessed by methylation-specific PCR and gene expression levels 
were measured using real-time Q-PCR analysis. The response of epend-
ymoma cell cultures in vitro to ADI-PEG20 was determined at various time 
points using the sulphorodamine B (SRB) assay. Promoter hypermethylation 
of ASS1 was present in 41.5% ependymoma (17/41 samples) and methyla-
tion correlated with down-regulation of ASS1 expression (p<0.0001, Fisher’s 
exact test). Importantly, methylation and expression status was maintained 
in 6 patient-derived cell cultures for which paired biopsies were available. 
Conversely, methylation of ASL was not detected in any samples. Treatment 
with ADI-PEG20 inhibited proliferation of ependymoma cells only in those 
cultures with methylation-dependent silencing of ASS1. Our findings sug-
gest that argininine depletion therapy may benefit a significant proportion 
of paediatric patients with intracranial ependymoma.
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